By Mill Chart
Last update: Feb 5, 2024
Discover MERCK & CO. INC. (NYSE:MRK), an undervalued stock highlighted by our stock screener. NYSE:MRK showcases solid financial health and profitability while maintaining an appealing valuation. We'll explore the details.
ChartMill employs its own Valuation Rating system for all stocks. This score, ranging from 0 to 10, is determined by evaluating different valuation factors, including price to earnings and free cash flow, both in absolute terms and relative to the market and industry. NYSE:MRK has earned a 7 for valuation:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NYSE:MRK has achieved a 7:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NYSE:MRK has achieved a 5 out of 10:
ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NYSE:MRK has earned a 4 for growth:
More Decent Value stocks can be found in our Decent Value screener.
Check the latest full fundamental report of MRK for a complete fundamental analysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
MERCK & CO. INC.
NYSE:MRK (4/23/2024, 7:14:02 PM)
After market: 127.05 +0.17 (+0.13%)126.88
-0.06 (-0.05%)
These are the low-beta and attractively valued stocks to buy for a market crash as they represent companies with strong fundamentals.
These are the undervalued pharmaceutical stocks to buy as they have a deep clinical pipeline which will driven earnings and cash flow growth.
/CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab),...
When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.
Although the idea of Dow stocks to buy now is patently boring, that could be a positive attribute amid the current backdrop.
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
Being able to stop a drug's unwanted effects could lead to a larger market share.
There's a new reason to believe that their joint projects are going well.
We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades.
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
MERCK & CO. INC. (NYSE:MRK): good value for what you're paying.